NCT07021027

Eggs and Age-related Macular Degeneration (EggsAMD) Study.

Feasibility Study of Whole Egg Consumption in Adults With Intermediate Age-related Macular Degeneration

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Kathryn Starr · Academic / Other
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

Age-related macular degeneration (AMD) is the primary cause of vision loss in people over the age of 55. Currently, no cure is available for individuals suffering from AMD. The purpose of this pilot study is to evaluate the feasibility of implementing a 5-month egg intervention in adults with intermediate AMD. The objective of this research study is to evaluate the feasibility of a whole egg (2 or 4 per day) intervention in older adults with intermediate AMD. The secondary objective of this research is to determine descriptive statistics, change over time and estimate effect sizes for retinal sensitivity, and vision, cognition and physical function. By completing these research objectives, the researchers hope to gain preliminary evidence in support of a larger trial that will assess the impact of egg consumption on eye health in adults with AMD.

Conditions

• Intermediate Age-Related Macular Degeneration

Interventions

Type	Name	Description
DRUG	Whole Egg - 4	Participants will be asked to consume 4 medium Eggland's Best eggs per day for 5 months.
DRUG	Whole Egg - 2	Participants will be asked to consume 2 medium Eggland's Best eggs per day for 5 months.

Timeline

• Start date: 2025-06-18
• Primary completion: 2026-09-30
• Completion: 2026-09-30
• First posted: 2025-06-13
• Last updated: 2026-01-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study